Thermo Fisher Scientific Inc $ 461.29 -7.3 (-1.56%)
Thermo Fisher Scientific Inc News and Headlines -
According to GuruFocus data, these stocks have reached their 52-week highs.
Cintas reached the 52-week high of $320.39
In its core uniform and facility services unit (81% of sales), Cintas Corp. (CTAS) provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels and restroom supplies. Cintas also runs a first aid and safety services business (10% of sales), a fire protection services business (6% of sales)
Andreas Halvorsen (Trades, Portfolio), founding partner and chief investment officer of Viking Global Investors, disclosed last week that his top five trades for the second quarter in terms of portfolio impact featured position trimmings of Netflix Inc. (NFLX) and Amazon.com Inc. (AMZN), a position boost of American Express Co. (AXP) and new holdings in Thermo Fisher Scientific Inc. (TMO) and Hilton Worldwide Holdings Inc. (HLT).
Prior to founding the Greenwich, Connecticut-based firm, Halvorsen worked as senior managing director at Julian Robertson (Trades, Portfolio)'s Tiger Management. Viking manages approximately $42 billion in total assets; according
According to the GuruFocus All-in-One Screener, a Premium feature, the stocks of the following guru-owned health care companies have outperformed the S&P 500 Index over the past 12 months through July 10.
UnitedHealth Group Inc. (UNH) has a market cap of $287.94 billion. It has outperformed the S&P 500 by 7.42% over the past year.
Shares are trading with a price-earnings ratio of 7.08. As of Friday, the share price was 61.74% above the 52-week low and 3.87% below the 52-week high.
The company has a GuruFocus profitability rating of 8 out of 10. The return on
Based in New York, the fund is managed by a nine-person team that invests based on a bottom-up stock selection process. The team looks for companies that have strong franchises, high and sustainable return on invested capital, strong free cash flow, difficult-to-duplicate intangible assets, good financial strength and capable management.
Based on the above investing criteria, the firm added the most to its holdings in Thermo Fisher Scientific Inc. (TMO), Philip Morris
Shares of Thermo Fisher Scientific Inc (TMO), American Water Works Co Inc (AWK) and Ormat Technologies Inc (ORA) have performed strongly over the past several years, beating the S&P 500 index in terms of larger share price gains.
The S&P 500 index, which is used as a benchmark for the U.S. stock market, gained 21% in the past year, 23% in the past two years and 46% in the past three years through Friday, Feb. 14.
The profitability of the these companies has worked as an essential catalyst to the share prices of their stocks over the observed periods. Should
Managed by a nine-person team, the New York-based fund invests in high-quality companies around the world in order to achieve long-term capital appreciation. It looks for companies that have resilient business franchises and growth potential.
Based on these criteria, the fund opened a position in Thermo Fisher Scientific Inc. (TMO) and closed out of its Clorox Co. (CLX) holding during the quarter.
Thermo Fisher Scientific
The portfolio managers
U.S. stocks were in the green on Wednesday as several companies were reporting quarterly financial results. The Dow Jones Industrial Average gained 0.22% to 26,847, the S&P 500 Index rose 0.20% to 3,001 and the Nasdaq Composite Index increased 0.16% to 8,116.
Non-index stocks also moved on Wednesday. Shares ofÂ Snap Inc. (SNAP)Â fell almost 6% on WednesdayÂ after the company announcedÂ third-quarter results on Tuesday. It posted a loss of 4 cents per share on $446.2Â m
U.S. stocks were in the green on Friday after the U.S. economy added 136,000 new jobs in September. Further, the unemployment rate declined to 3.5%, the lowest rate since December 1969. The Dow Jones Industrial Average gained 1.09% to 26,487, the S&P 500 Index jumped 1.11% to 2,942 and the Nasdaq Composite Index advanced 1.17% to 7,964.
Shares ofÂ Smart Global Holdings Inc. (SGH)Â gainedÂ almost 8% on FridayÂ after announcingÂ fourth-quarter results. The company posted earnings of 50 centsÂ per share
Among health care companies, those with medical device businesses are likely to be the hardest hit by the ongoing tariff war with China. One consolation is that industry members aren’t slated to be as heavily impacted as many other businesses. But that could change.
USA TodayÂ reported in early July that Brandon Henry, an analyst with RBC Capital Markets, wrote in a note that theÂ U.S. imports about $6 billion in medical technology from China, while China imports about $4 billion in U.S. medical tech.
The biggest U.S. medical device companies include Medtronic (MDT), Thermo Fisher
When Kevin Conroy was recruited for the top job at Exact Sciences Corp. (EXAS), he knew it would require a leap of faith to take on the role. After all, the Madison, Wisconsin-based cancer diagnostics company had an unenviable track record and an uncertain future.
Exact had been unsuccessful twice in developing colorectal cancer screening tests, was quickly depleting its cash and had a pipeline that didn’t inspire a great deal of confidence. These issues were reflected in the company’s share price of about $2.65. That was even lower than its initial public offering price in 2001.
My, how things
Regeneron Pharmaceuticals Inc. (REGN) shareholders ought to take time to toast the company’s president and CEO, Leonard Schleifer. In the time he’s been at the helm of the Tarrytown, New York-based biotech, the company’s share price is up about 3,300% to $417. Schleifer earned $26.5 million in 2017, according to an article in Genetic Engineering & Biotechnology News. So if you divide the percentage increase in company shares since he’s been CEO by every million earned, the multiple is nearly 124, far and away the best among his peers.
Now while this is a somewhat arbitrary way of
It’s said that a rising tide lifts all boats, and that axiom might apply to many of the “lesser” companies in the market for animal and pet diagnostic testing. Right now it’s pretty much IDEXX Laboratories Inc. (IDEXX) and everyone else. But some of those trailing the leader might be buoyed by their participation in a market that is forecasted to grow at a compound rate of more than 9% through 2022, reaching more than $3.6 billion, according to leading market intelligence firm Reportbuyer.
One of the reasons is that people are buying more pet health insurance. By 2017, Americans
The stock traded well above $300 before the recent downturn. It has a price-earnings ratio of nearly 70 and a lofty valuation of more than $45 billion. Its price has tripled in the past five years and is up more than 50% from its 52-week low, owing in part to renewed enthusiasm for the biotechnology industry. Does it warrant a look, or even your investment dollars?
It does if it’s Illumina Inc. (ILMN). The San Diego-based gene sequencing company is an American success story. Only 30 years old, it pretty much owned the gene sequencing market when it recently added
Earlier in the month, Illumina (ILMN) made an aggressive and surprising move: acquiring Pacific Biosciences (PACB), one of its direct competitors, for $1.2 billion. To date, this is the largest acquisition that Illumina has ever made.
Currently, Illumina is king of the hill when it comes to DNA sequencing, and despite intense competition from companies such as Thermo Fisher Scientific (TMO), Agilent Technologies (A) and QIAGEN (QGEN), Illumina has continued to steadily grow and expand into new markets year after year.
The reason for this growth
U.S. stock market indexes fell on Wednesday, with the S&P 500 posting its sixth day of losses. The Dow Jones Industrial Average tumbled more than 200 points, or 0.86%, to 24,970, the S&P 500 index declined 1.11% to 2,710 and the Nasdaq Composite Index fell 1.53% to 7,324.
Shares of Texas Instruments Inc. (TXN) slid more than 4% on Wednesday morning after the company posted third-quarter earnings of $1.58 per share on $4.26 billion in revenue, reflecting 3.6% year-over-year growth. The company beat earnings estimates by 5 cents, but fell $40 million short of revenue expectations.
Analog revenue rose 8%,
Andreas Halvorsen (Trades, Portfolio)’s Viking Global Investors disclosed Thursday that it holds a 75.6% stake in urologic biopharmaceutical company Urovant Sciences Ltd. (UROV) through its private backing of the company’s parent.
Halvorsen made the holding known because Urovant went public on Oct. 1. The company originated as one of 13 “Vants” developed by umbrella owner Roivant Sciences. Each “Vant” focuses on research, development and commercialization of treatments for a specified disease. Founded by Vivek Ramaswamy in 2014, the Switzerland-based Roivant often acquires promising drugs discarded by larger biopharmaceutical companies.
Hedge fund Viking Global became involved when it
The guru reduced his Oracle Corp. (ORCL) holding by 48.85%. The trade had an impact of -2.61% on the portfolio.
The company, which sells enterprise information technology solutions, has a market cap of $179.58 billion and an enterprise value of $178.11 billion.
GuruFocus gives the company a profitability and growth rating of 7 out of 10. While the return on equity of 7.97% is outperforming the
Guru investor Steven Cohen (Trades, Portfolio), who heads up the multibillion-dollar hedge fund Point72 Asset Management, disclosed he established a 5.2% stake in Nightstar Therapeutics Ltd. (NITE) on Aug. 6, adding to his holdings in the health care space.
With approximately $13 billion in assets under management, the Connecticut-based firm seeks to deliver superior risk-adjusted returns using long, short, macro and systematic strategies. Cohen founded Point72 in 2014 after his former hedge fund, S.A.C. Capital Advisors, was shut down following an insider trading investigation.
According to GuruFocus real-time picks, Cohen invested in 1.5 million shares of
Steven Romick (Trades, Portfolio) is the portfolio manager of the FPA Crescent Fund. The guru's 63-stock portfolio has a total value of $10.6 billion. According to the GuruFocus All-In-One Screener, the following stocks are the best performers in his portfolio on a 12-month basis.Â
Thermo Fisher Scientific Inc. (TMO)
The health care company has a GuruFocus profitability and growth rating of 8 out
According to the GuruFocus All-in-One Screener, the following stocks have high business predictability ratings and positive total returns over the past six months. At least five gurus are shareholders of these companies.
TransDigm Group Inc. (TDG), which has a market cap of $18.94 billion, produces engineered aircraft components for commercial and military use. GuruFocus gave the company a business predictability rating of five out of five stars.
The stock has risen 30.4% since the beginning of the year and is trading with a price-earnings ratio of 27.99. The price has been as high as $368.34 and as